Published in Drug Alcohol Depend on July 02, 2011
Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. PLoS One (2015) 0.81
Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol (2012) 0.80
Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections. PLoS One (2015) 0.79
Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis. BMC Infect Dis (2016) 0.79
Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science (1998) 25.53
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med (1992) 9.10
Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet (1999) 8.91
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 7.36
Course and outcome of hepatitis C. Hepatology (2002) 6.51
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol (1992) 6.09
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Epidemiology of hepatitis C in the West. Semin Liver Dis (1995) 2.77
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med (1995) 2.61
High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS (1995) 1.93
Transitions to injecting drug use among noninjecting heroin users: social network influence and individual susceptibility. J Acquir Immune Defic Syndr (2006) 1.88
Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis (2001) 1.77
Hepatitis C virus load and survival among injection drug users in the United States. Hepatology (2005) 1.66
Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend (2008) 1.60
Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend (2007) 1.50
Determinants of the quantity of hepatitis C virus RNA. J Infect Dis (2000) 1.32
Prevalence, incidence, and correlates of chlamydia and gonorrhea among young adult injection drug users. J Subst Abuse (2001) 1.22
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol (2008) 1.15
A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol (2009) 1.14
Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol (1996) 1.07
Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol (1996) 1.04
Hepatitis C in African Americans. J Clin Gastroenterol (2007) 1.03
Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat (2001) 0.92
Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection. J Viral Hepat (2002) 0.90
Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group. J Hepatol (1996) 0.88
Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J Acquir Immune Defic Syndr (2006) 0.87
Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology (1998) 0.87
Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load. Am J Kidney Dis (1994) 0.83
Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver (1999) 0.83
Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor Monitor. J Clin Microbiol (1998) 0.82
A case-control study of the factors associated with spontaneous resolution of hepatitis C viremia. Am J Gastroenterol (1999) 0.82
Prevalence and correlates of former injection drug use among young noninjecting heroin users in Chicago. Subst Use Misuse (2010) 0.81
The influence of host factors on the natural history of chronic hepatitis C viral infections. J Viral Hepat (1999) 0.79
The utility of indirect predictors of hepatitis C viremia. Drug Alcohol Depend (2004) 0.77
No significant changes in levels of hepatitis C virus (HCV) RNA by competitive polymerase chain reaction in blood samples from patients with chronic HCV infection. Dig Dis Sci (1997) 0.77
A potential decline in life expectancy in the United States in the 21st century. N Engl J Med (2005) 19.63
Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol (2002) 4.20
A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS (2007) 3.58
Simultaneous recruitment of drug users and men who have sex with men in the United States and Russia using respondent-driven sampling: sampling methods and implications. J Urban Health (2009) 3.00
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis (2010) 2.62
Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology (2006) 1.93
Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis (2008) 1.86
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol (2010) 1.78
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend (2008) 1.60
Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol (2009) 1.56
Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend (2007) 1.50
Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend (2007) 1.50
Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med (2008) 1.42
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol (2007) 1.41
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS (2009) 1.36
Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care (2011) 1.31
Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int (2007) 1.30
Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology (2003) 1.26
Comparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities. J Urban Health (2004) 1.26
Needle exchange and injection-related risk behaviors in Chicago: a longitudinal study. J Acquir Immune Defic Syndr (2007) 1.24
The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med (2009) 1.23
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol (2008) 1.22
Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr (2004) 1.22
Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS (2009) 1.17
Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend (2009) 1.12
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology (2009) 1.11
A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med (2007) 1.09
Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling. J Hepatol (2012) 1.09
Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther (2009) 1.08
The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am J Gastroenterol (2009) 1.08
Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS (2004) 1.06
Prevalence and correlates of crack-cocaine injection among young injection drug users in the United States, 1997-1999. Drug Alcohol Depend (2005) 1.06
Prevalence of psychiatric disorders among young injection drug users. Drug Alcohol Depend (2012) 1.04
Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol (2007) 1.03
Lessons learned from Chicago's emergency response to mass evacuations caused by Hurricane Katrina. Am J Public Health (2009) 1.03
TIPS for treatment of variceal hemorrhage: clinical outcomes in 128 patients at a single institution over a 12-year period. J Vasc Interv Radiol (2011) 1.02
Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA. AIDS (2003) 1.00
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS (2010) 1.00
Underreporting of blood and body fluid exposures among health care students and trainees in the acute care setting: a 2007 survey. Am J Infect Control (2011) 0.99
Differences in sexual identity, risk practices, and sex partners between bisexual men and other men among a low-income drug-using sample. J Urban Health (2009) 0.99
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2011) 0.99
Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach. Hepatology (2014) 0.98
Maternal neutralizing antibody and transmission of hepatitis C virus to infants. J Infect Dis (2008) 0.97
Relationship characteristics associated with anal sex among female drug users. Sex Transm Dis (2010) 0.97
The use of needle exchange by young injection drug users. J Acquir Immune Defic Syndr (2003) 0.97
Needle exchange and sexual risk behaviors among a cohort of injection drug users in Chicago, Illinois. Sex Transm Dis (2009) 0.97
Colonization or infection with multidrug-resistant Acinetobacter baumannii may be an independent risk factor for increased mortality. Clin Infect Dis (2006) 0.96
Identifying hidden sexual bridging communities in Chicago. J Urban Health (2009) 0.96
Escherichia coli and Klebsiella pneumoniae carbapenemase in long-term care facility, Illinois, USA. Emerg Infect Dis (2009) 0.96
Rebleeding rates following TIPS for variceal hemorrhage in the Viatorr era: TIPS alone versus TIPS with variceal embolization. Hepatol Int (2010) 0.96
Cessation of injection drug use and change in injection frequency: the Chicago Needle Exchange Evaluation Study. Addiction (2006) 0.96
p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol (2005) 0.95
The relative role of perceived partner risks in promoting condom use in a three-city sample of high-risk, low-income women. AIDS Behav (2011) 0.95
Liver transplantation for hepatocellular carcinoma: a survey of practices. J Clin Gastroenterol (2006) 0.94
Development, description, and acceptability of a small-group, behavioral intervention to prevent HIV and hepatitis C virus infections among young adult injection drug users. Drug Alcohol Depend (2007) 0.94
Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology (2005) 0.92
Drug use and HIV risk practices of secondary and primary needle exchange users. AIDS Educ Prev (2005) 0.91
FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis. Hepatology (2014) 0.90
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver Int (2014) 0.90
Gender differences in baseline health, needs at release, and predictors of care engagement among HIV-positive clients leaving jail. AIDS Behav (2013) 0.90
Laboratory diagnosis and nonoperative management of biliary complications in living donor liver transplant patients. J Clin Gastroenterol (2007) 0.90
Heroin insufflation as a trigger for patients with life-threatening asthma. Chest (2003) 0.89
Changes in the sharing of drug injection equipment among street-recruited injection drug users in Chicago, Illinois, 1994--1996. Subst Use Misuse (2005) 0.89
Predictors and correlates of reduced frequency or cessation of injection drug use during a randomized HIV prevention intervention trial. Addiction (2010) 0.87
Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation (2012) 0.87
Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J (2009) 0.87
Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago. Drug Alcohol Depend (2010) 0.86
Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med (2010) 0.85
Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes. Appl Immunohistochem Mol Morphol (2006) 0.85
Barriers to treatment of hepatitis B in an urban Chinatown community. J Clin Gastroenterol (2012) 0.85
Hepatitis B virus clearance rate estimates. Hepatology (2009) 0.84
Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci (2008) 0.83
Physical activity and metabolic syndrome in liver transplant recipients. Liver Transpl (2013) 0.82
Misdirected opposition: Evidence opposing "not in my back yard" arguments against syringe exchange programmes. Int J Drug Policy (2010) 0.82
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antivir Ther (2014) 0.82
Simple clinical variables predict liver histology in hepatitis C: prospective validation of a clinical prediction model. Scand J Gastroenterol (2005) 0.82
Liver Injury with Features Mimicking Autoimmune Hepatitis following the Use of Black Cohosh. Case Rep Med (2010) 0.82
Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology (2003) 0.82
Sexual risk behavior associated with transition to injection among young non-injecting heroin users. AIDS Behav (2013) 0.82
Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol (2013) 0.82
Prevalence and correlates of former injection drug use among young noninjecting heroin users in Chicago. Subst Use Misuse (2010) 0.81
Gender-Related Risk Factors Improve Mortality Predictive Ability of VACS Index Among HIV-Infected Women. J Acquir Immune Defic Syndr (2015) 0.81
Enteric pathogens in stool samples of Chicago-area water recreators with new-onset gastrointestinal symptoms. Water Res (2012) 0.79
How physicians describe outcomes to HCV therapy: prevalence and meaning of "cure" during provider-patient in-office discussions of HCV. J Clin Gastroenterol (2008) 0.79
Mode of delivery and postpartum HIV-1 disease progression: the Women and Infants Transmission Study. AIDS (2006) 0.79
Characterization of antigenic variants of hepatitis C virus in immune evasion. Virol J (2011) 0.79
The relationship between vaccine refusal and self-report of atopic disease in children. J Allergy Clin Immunol (2005) 0.79
Prescription opioid misuse and mental health among young injection drug users. Am J Drug Alcohol Abuse (2014) 0.79
Prevalence and correlates of suspected nonalcoholic fatty liver disease in Chinese American children. J Clin Gastroenterol (2015) 0.78
Predictors and outcomes of antibiotic adequacy for bloodstream infections in veterans with spinal cord injury. Arch Phys Med Rehabil (2009) 0.78
FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma. Gene Expr (2016) 0.78
Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C. Transplantation (2014) 0.78
Viral kinetics in the treatment of chronic hepatitis C. J Viral Hepat (2006) 0.78
Black cohosh (Actaea racemosa) for the mitigation of menopausal symptoms: recent developments in clinical safety and efficacy. Womens Health (Lond Engl) (2006) 0.78
Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. AIDS Behav (2013) 0.78
One medicine, one university: the DVM/MPH program at the University of Illinois. J Vet Med Educ (2008) 0.78
Management of hepatitis B in liver transplant patients. J Clin Gastroenterol (2005) 0.77
Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. Ann Hepatol (2013) 0.77